A vaccine for nicotine addiction
Cytos Biotechnology has announced that it has entered into an exclusive global commercial licence agreement with Novartis to develop, manufacture and commercialise CYT002-NicQb, a therapeutic vaccine in phase II clinical development for the treatment of nicotine addiction.
The vaccine has been shown to induce nicotine-specific antibodies that bind to nicotine in the bloodstream. As the resulting complex of nicotine attached to an antibody is too large to cross the blood-brain barrier, nicotine uptake into the brain and the subsequent stimulation of nicotine-responsive nerve cells is believed to be significantly reduced.
The reward-inducing and addiction-driving stimulus of nicotine should be minimised and abstinence from smoking more easily achieved and maintained.
A phase I and a phase II clinical trial have demonstrated that CYT002-NicQb has a favourable safety profile, is generally well tolerated and that it promoted and sustained long-term abstinence from smoking, when high antibody levels have been achieved on vaccination.
According to a World Health Organisation study in 2006, there are 1.3 billion smokers worldwide and 4.9 million tobacco-related deaths per year, making tobacco use the leading cause of preventable death in the world today.
Light-powered DNA detection removes the need for PCR
Unlike PCR, which amplifies DNA sequences by making millions of copies of target DNA for...
Early Parkinson's detection with an RNA-based blood test
The test has the potential to alleviate the uncertainty faced by patients and clinicians,...
Biomarkers for SIDS found in blood samples
US researchers have revealed the fingerprints of sudden infant death syndrome (SIDS) within blood...
